Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China; Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China, China.
Department of VIP Service, Peking University School and Hospital of Stomatology, Beijing, China.
Biomed Pharmacother. 2017 Dec;96:434-442. doi: 10.1016/j.biopha.2017.09.149. Epub 2017 Oct 12.
The low median survival rate of oral squamous cell carcinoma (OSCC) is associated with chemotherapeutic resistance. Niclosamide is an oral anti-helminthic drug, its anti-cancer effect has been reported in recent years. However, the effect of niclosamide on OSCC remains largely unknown. In this study, we, for the first time, investigated the underlying mechanisms from cell cycle arrest and let-7a/STAT3 axis through CCK-8, cell cycle, apoptosis, wound healing, Transwell invasion, generation of stable cell line, real-time PCR, and western blot assays using two OSCC cell lines WSU-HN6 and Tca83. We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated. Furthermore, niclosamide could inhibit migration and invasion of OSCC through upregulation of let-7a expression and downregulation of p-STAT3 expression. What is more, we established the stably expressing let-7a cell line (HN6-let-7a). Like niclosamide, HN6-let-7a could decrease the ability of the cell migration, invasion as well as the expression of p-STAT3. Collectively, our study finds the new mechanisms that niclosamide inhibits OSCC proliferation through causing cell cycle arrest in G1 phase via downregulation of the above cell cycle-related genes; promotes OSCC apoptosis through upregulation of pro-apoptotic genes; decreases migration and invasion of OSCC by let-7a/STAT3 axis, thus providing a preferred therapeutic candidate for OSCC in future.
口腔鳞状细胞癌(OSCC)的中位生存率较低与化疗耐药有关。尼氯硝唑是一种口服驱虫药,近年来其抗癌作用已有报道。然而,尼氯硝唑对 OSCC 的作用在很大程度上尚不清楚。在这项研究中,我们首次通过 CCK-8、细胞周期、凋亡、划痕愈合、Transwell 侵袭、稳定细胞系的建立、实时 PCR 和 Western blot 分析,从细胞周期停滞和 let-7a/STAT3 轴研究了其潜在机制,使用了两种 OSCC 细胞系 WSU-HN6 和 Tca83。我们表明,尼氯硝唑可以通过诱导 G1 期细胞周期停滞和促进细胞凋亡来抑制 OSCC 细胞增殖,而细胞周期相关蛋白 MCM2、MCM7、CDK2 和 CDK4 下调,凋亡相关蛋白 p53 和 cleaved caspase-3 上调。此外,尼氯硝唑可以通过上调 let-7a 表达和下调 p-STAT3 表达来抑制 OSCC 的迁移和侵袭。更重要的是,我们建立了稳定表达 let-7a 的细胞系(HN6-let-7a)。与尼氯硝唑一样,HN6-let-7a 可以降低细胞迁移、侵袭能力以及 p-STAT3 的表达。综上所述,我们的研究发现了新的机制,即尼氯硝唑通过下调上述细胞周期相关基因使 OSCC 通过 G1 期细胞周期停滞抑制 OSCC 增殖;通过上调促凋亡基因促进 OSCC 凋亡;通过 let-7a/STAT3 轴降低 OSCC 的迁移和侵袭,从而为未来 OSCC 的治疗提供了一个优选的候选药物。
Artif Cells Nanomed Biotechnol. 2019-12
Int J Mol Sci. 2017-1-12
Cell Physiol Biochem. 2018
Anticancer Agents Med Chem. 2019
Head Neck Pathol. 2023-6
Int J Mol Sci. 2022-12-17